Product Name:Arformoterol tartrate
CAS:200815-49-2 
Appearance:white Powder
Assay:98%

Uses for Arformoterol Tartrate
Long-term treatment of bronchoconstriction associated with COPD, including chronic bronchitis and emphysema
Long-acting β2-adrenergic agonists recommended as maintenance therapy in patients with moderate (e.g., forced expiratory volume in 1 second [FEV1] ≥50 but <80% of predicted) to very severe COPD (e.g., FEV1 <30% of predicted or <50% of predicted plus chronic respiratory failure) who have persistent symptoms not relieved by as-needed therapy with short-acting bronchodilators (e.g., ipratropium, β2-adrenergic agonist).
Regular treatment with long-acting bronchodilators more effective and convenient than treatment with short-acting bronchodilators. Superiority of one long-acting bronchodilator over another currently not established. If inadequate response, may use a combination of long-acting bronchodilators, such as a long-acting inhaled anticholinergic agent (tiotropium) and a long-acting β2-adrenergic agonist.
In patients with severe (e.g., FEV1 <50% of predicted, history of repeated exacerbations) to very severe COPD, add regular treatment with an inhaled corticosteroid to long-acting bronchodilator therapy.5 9 11If inadequate response or limiting adverse effects occur, add or substitute extended-release oral theophylline.
Not to be used for immediate relief of acute exacerbations of COPD.1 6 Use short-acting inhaled β2-agonist intermittently (as needed) for acute symptoms of COPD.1 5 (See Acute Exacerbations of COPD under Cautions.) Efficacy and safety of long-acting bronchodilators, with or without inhaled corticosteroids, during acute exacerbations of COPD not established.